Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Pfizer 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Pfizer 3Q

Lipitor patent expiry hurts results

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer

3Q Revenues: $14.0 billion (-16%) 

3Q Earnings:  $3.2 billion (-14%)

YTD Revenues: $43.9 billion (-11%)

YTD Earnings: $8.3 billion (-4%)

Comments: Biopharma revenues were $12.1 billion in the quarter, down 18%. Primary care revenues were down 39% to $3.6 billion. Specialty care revenues were $3.4 billion down 10%. Established products sales were up 7% to $2.4 billion. U.S. revenues were $5.6 billion, down 18% and International revenues were $8.3 billion, down 14%, primarily due to the loss of exclusivity of Lipitor (down 71% to $749 million) and the unfavorable impact of foreign exchange of $699 million, or 4%. Lyrica sales were up 14% to $1.0 billion. Prevnar 13/Prevenar 13 sales were down 14% to $868 million. Celebrex sales were up 7% to $676 million. Viagra sales were up 7% to $517 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters